Close

pCDCAR1 PSCA h(DAP12) (CAR-MZ091)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-PSCA chimeric antigen receptor (CAR) is constructed for the engineering of NK cells to target human PSCA. The NK cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-PSCA antibody linked to DAP12 signaling domains. And the vector product was designed for the treatment of PSCA-positive tumors.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • PSCA
  • Targeting Cell Type
  • NK cell
  • Targeting Diseases
  • PSCA-positive tumors
  • Generation
  • First
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Receptor Construction
  • scFv-DAP12
  • Discription of Signaling Cassetes
  • DAP12
    DAP12 is a 12 kDa transmembrane protein recently recognized as a key signal transduction receptor element in Natural Killer (NK) cells. It is a disulfide-linked homodimer that non-covalently associates with several activating receptors expressed on NK cells.

Target

  • Clone
  • AM1
  • Host
  • Human
  • Target Species
  • Human
  • Gene Name
  • prostate stem cell antigen
  • Synonyms
  • PSCA;PSCA; prostate stem cell antigen; PRO232;

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 Binding studies for functional characterization of scFvs and scFv-BAPs via the c-myc epitope for validation of mono-biotinylated scFv(h-AM1)-BAP and scFv(MR1.1)-BAP were undertaken using fow cytometry.

CAR Construction : Latest CAR Construction

Fig.1 Binding studies for functional characterization of scFvs and scFv-BAPs via the c-myc epitope for validation of mono-biotinylated scFv(h-AM1)-BAP and scFv(MR1.1)-BAP were undertaken using fow cytometry.

Open histograms represent staining controls using only secondary antibodies.

Schau, I., Michen, S., Hagstotz, A., Janke, A., Schackert, G., Appelhans, D., & Temme, A. (2019). Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis. Scientific Reports, 9(1), 3299.

CAR scFv data FCM

Fig.2 scFv(h-AM1)-BAP-RICIA-induced apoptosis in HEK-BluehTLR3/PSCA cells was analyzed via Annexin V-FITC/PI staining.

CAR Construction : Latest CAR Construction

Fig.2 scFv(h-AM1)-BAP-RICIA-induced apoptosis in HEK-BluehTLR3/PSCA cells was analyzed via Annexin V-FITC/PI staining.

Data are represented as mean±s.d.

Schau, I., Michen, S., Hagstotz, A., Janke, A., Schackert, G., Appelhans, D., & Temme, A. (2019). Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis. Scientific Reports, 9(1), 3299.

CAR scFv data FCM

Fig.3 Crosslinking of scFv(h-AM1) causes signifcant PSCA receptor internalization on HEK293TPSCA cells in a time-dependent manner.

CAR Construction : Latest CAR Construction

Fig.3 Crosslinking of scFv(h-AM1) causes signifcant PSCA receptor internalization on HEK293TPSCA cells in a time-dependent manner.

Internalization of PSCA afer treatment with monovalent or crosslinked scFv(h-AM1) was assessed via fow cytometry.

Schau, I., Michen, S., Hagstotz, A., Janke, A., Schackert, G., Appelhans, D., & Temme, A. (2019). Targeted delivery of TLR3 agonist to tumor cells with single chain antibody fragment-conjugated nanoparticles induces type I-interferon response and apoptosis. Scientific Reports, 9(1), 3299.

CAR scFv data FCM

Fig.4 Targeted delivery of scFv (AM1)-P-BAP-guided polyplexes in PSCA-positive cells.

CAR Construction : Latest CAR Construction

Fig.4 Targeted delivery of scFv (AM1)-P-BAP-guided polyplexes in PSCA-positive cells.

Data are represented as mean±s.d.

Jugel, W., Aigner, A., Michen, S., Hagstotz, A., Ewe, A., Appelhans, D., ... & Tietze, S. (2021). Targeted RNAi of BIRC5/survivin using antibody-conjugated poly (propylene imine)-based polyplexes inhibits growth of PSCA-positive tumors. Pharmaceutics, 13(5), 676.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-PSCA (AM1) h(DAP12) CAR, pCDCAR1 (CAR-MZ091). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.